Ernexa Therapeutics Inc. Common Stock

ERNANASDAQ • USD
1.66 USD
↘ 0.03 (2.07%)🟢PRE MARKET (AS OF 08:53 AM EST)
🟢Market: OPEN

Ernexa Therapeutics Inc. Common Stock (ERNA) is currently trading at $1.66. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ERNA is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$1.72
High?$1.72
Low?$1.62
Prev. Close?$1.69
Volume?1.1K
Avg. Volume?48.6K
VWAP?$1.64
Rel. Volume?0.02x
Bid / Ask
Bid?$1.45 × 100
Ask?$2.15 × 100
Spread?$0.70
Midpoint?$1.80
Valuation & Ratios
Market Cap?2.9M
Shares Out?1.7M
Float?940.3K
Float %?57.6%
P/E Ratio?N/A
P/B Ratio?0.66
EPS?-$8.26
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Employees
5
Market Cap
2.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-03-26
Address
1035 CAMBRIDGE STREET
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?-56.41Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.54%Low
Short Interest?33.3K
Days to Cover?2.0
Free Float940.3K
Avg Daily Volume16.4K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.57Strong
Quick Ratio?2.57Strong
Cash Ratio?2.13Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.66CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-321.2%WEAK▾
ROA?
S&P
3
-196.7%WEAK▾
Cash Flow & Enterprise
FCF?$-10754000
Enterprise Value?$-2714591
Fundamentals ratios updated end of day